Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8758607 | 0.79 | MAPT (0.35) | ALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL12036727 | 0.75 | AAK1 (0.41) | KDM4E | |
| SCHEMBL6709710 | 0.73 | S1PR4 (0.36) | — | |
| SCHEMBL8757626 | 0.72 | PDE10A (0.36) | PTGDR2ALDH1A1PDE10AKCNJ6KCNJ3 | |
| SCHEMBL8757587 | 0.72 | PDE10A (0.35) | PTGDR2ALDH1A1NPC1RAB9APDE10A | |
| SCHEMBL8756833 | 0.72 | PDE10A (0.35) | PTGDR2ALDH1A1NPC1RAB9APDE10A | |
| SCHEMBL8755721 | 0.72 | PDE10A (0.36) | PTGDR2ALDH1A1PDE10AKCNJ6KCNJ3 | |
| SCHEMBL8757569 | 0.71 | PDE10A (0.34) | PTGDR2PDE10AKCNJ6KCNJ3PTGDR | |
| SCHEMBL8818362 | 0.71 | MBOAT4 (0.32) | PDE10A | |
| SCHEMBL8757753 | 0.71 | PDE10A (0.33) | PDE10AKCNJ6KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459185-B | Novel thyroid hormone beta receptor agonist | MITSUBISHI TANABE PHARMA CORP | 2015-06-03 | — | — | CN | disclosed |
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| EP-2423194-B1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| CN-102459185-A | Novel thyroid hormone beta receptor agonist | MITSUBISHI TANABE PHARMA CORP | 2012-05-16 | — | — | CN | disclosed |
| EP-2423194-A1 | NOVEL THYROID HORMONE beta RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, TSHR, THRA | PTGDR2 284/4885ALDH1A1 1797/4885KDM4E 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.